TaiGen Biopharmaceuticals Holdings Limited (TPEX: 4157)
14.50
+0.55 (3.94%)
Sep 10, 2024, 1:30 PM CST
TaiGen Biopharmaceuticals Holdings Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Net Income | 235.16 | 136.73 | -237.16 | 775.62 | -404.82 | -295.69 | Upgrade
|
Depreciation & Amortization | 25.6 | 27.48 | 28.46 | 28.74 | 30.86 | 33.54 | Upgrade
|
Other Amortization | 0.13 | 0.13 | 0.09 | 0.12 | 0.57 | 0.78 | Upgrade
|
Loss (Gain) From Sale of Assets | - | - | - | 0.08 | -0.01 | - | Upgrade
|
Asset Writedown & Restructuring Costs | - | - | 12.06 | - | 2.92 | - | Upgrade
|
Loss (Gain) From Sale of Investments | -173.86 | -165.22 | -0.3 | -0.08 | -0.43 | -151.89 | Upgrade
|
Loss (Gain) on Equity Investments | - | - | - | 23.24 | 113.04 | 133.96 | Upgrade
|
Stock-Based Compensation | 36.07 | 25 | -4.99 | 40.03 | 14.44 | - | Upgrade
|
Provision & Write-off of Bad Debts | 7.6 | 7.6 | - | - | - | - | Upgrade
|
Other Operating Activities | -67.84 | 1.22 | -60.88 | 40.07 | -20.94 | 31.39 | Upgrade
|
Change in Accounts Receivable | -3.1 | 1.83 | 260.02 | -272.8 | -5.44 | 0.33 | Upgrade
|
Change in Inventory | -32.42 | -18.75 | 3.29 | -4.35 | -7.13 | 3.16 | Upgrade
|
Change in Accounts Payable | 0.66 | 0.66 | -17.33 | 10.49 | -1.49 | -31.6 | Upgrade
|
Change in Unearned Revenue | -0.15 | -0.15 | -0.16 | -44.41 | 44.06 | -0.32 | Upgrade
|
Change in Income Taxes | - | - | - | 26.29 | 0.29 | -2.77 | Upgrade
|
Change in Other Net Operating Assets | 25.15 | -9.05 | -4.37 | -2.68 | -2.26 | -15.93 | Upgrade
|
Operating Cash Flow | -196.93 | 7.46 | -21.27 | 629.07 | -242.1 | -342.52 | Upgrade
|
Capital Expenditures | -1.04 | -3.89 | -3.39 | -10.24 | -5.46 | -3.87 | Upgrade
|
Sale of Property, Plant & Equipment | - | - | - | 0.11 | 0.01 | - | Upgrade
|
Sale (Purchase) of Intangibles | -3.47 | -3.51 | -4.07 | -1.6 | -2.95 | -1.2 | Upgrade
|
Investment in Securities | 256.82 | 138.44 | -81.62 | -298.07 | 216.76 | 315.06 | Upgrade
|
Other Investing Activities | 21.5 | 14.42 | 4.13 | 3.73 | 7.74 | 12.21 | Upgrade
|
Investing Cash Flow | 273.81 | 145.46 | -84.95 | -306.07 | 216.1 | 322.2 | Upgrade
|
Short-Term Debt Issued | - | - | 3 | - | - | 30 | Upgrade
|
Total Debt Issued | - | - | 3 | - | - | 30 | Upgrade
|
Short-Term Debt Repaid | - | -3 | - | - | -30 | - | Upgrade
|
Long-Term Debt Repaid | - | -16.99 | -17.99 | -18.61 | -19.07 | -20.97 | Upgrade
|
Total Debt Repaid | -15.81 | -19.99 | -17.99 | -18.61 | -49.07 | -20.97 | Upgrade
|
Net Debt Issued (Repaid) | -15.81 | -19.99 | -14.99 | -18.61 | -49.07 | 9.03 | Upgrade
|
Issuance of Common Stock | - | - | - | - | 0.02 | 1.13 | Upgrade
|
Other Financing Activities | -1.6 | -1.14 | -0.85 | -0.24 | -0.6 | -1.03 | Upgrade
|
Financing Cash Flow | -17.4 | -21.12 | -15.84 | -18.85 | -49.65 | 9.13 | Upgrade
|
Foreign Exchange Rate Adjustments | 1.3 | -0.25 | 0.24 | -0.07 | 0.25 | -0.66 | Upgrade
|
Net Cash Flow | 60.77 | 131.55 | -121.82 | 304.08 | -75.4 | -11.85 | Upgrade
|
Free Cash Flow | -197.97 | 3.57 | -24.66 | 618.83 | -247.56 | -346.39 | Upgrade
|
Free Cash Flow Margin | -132.46% | 2.90% | -68.06% | 47.80% | -1056.95% | -1705.17% | Upgrade
|
Free Cash Flow Per Share | -0.27 | 0.00 | -0.03 | 0.86 | -0.35 | -0.48 | Upgrade
|
Cash Interest Paid | 1.14 | 1.14 | 0.85 | 0.24 | 0.6 | 1.03 | Upgrade
|
Cash Income Tax Paid | 9.83 | 9.83 | 32.22 | 72.51 | 3.23 | - | Upgrade
|
Levered Free Cash Flow | -58.59 | -84.51 | 57.08 | 366.39 | -111.98 | -193.26 | Upgrade
|
Unlevered Free Cash Flow | -57.59 | -83.8 | 57.61 | 366.55 | -111.61 | -192.62 | Upgrade
|
Change in Net Working Capital | 4.57 | 19.82 | -215.06 | 252.68 | -43.01 | 48.67 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.